Fostemsavir:一种一流的HIV-1附着抑制剂。

IF 4.5 3区医学 Q2 IMMUNOLOGY Current Opinion in HIV and AIDS Pub Date : 2022-01-01 DOI:10.1097/COH.0000000000000712

Philip M Grant, Michael J Kozal

{"title":"Fostemsavir:一种一流的HIV-1附着抑制剂。","authors":"Philip M Grant, Michael J Kozal","doi":"10.1097/COH.0000000000000712","DOIUrl":null,"url":null,"abstract":"Purpose of review: Fostemsavir is a recently Food and Drug Administration-approved HIV-1 attachment inhibitor that binds to HIV-1 gp120 and prevents viral attachment to the cellular CD4 receptor. Here, we review the pharmacology, efficacy, tolerability, and resistance profile of fostemsavir.Recent findings: Fostemsavir is well tolerated and maintains virologic activity in individuals harboring multidrug-resistant HIV-1. In conjunction with optimal background therapy, a majority of heavily treatment-experienced clinical trial participants treated with fostemsavir achieved virologic suppression.Summary: The approval of fostemsavir represents an important advance for individuals harboring multidrug resistant HIV-1 due to its novel mechanism of action and lack of cross-resistance to other antiretrovirals. Further study will better define the role of resistance testing for fostemsavir and fostemsavir's potential role outside of salvage therapy in heavily treatment-experienced individuals.","PeriodicalId":10949,"journal":{"name":"Current Opinion in HIV and AIDS","volume":null,"pages":null},"PeriodicalIF":4.5000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":"{\"title\":\"Fostemsavir: a first-in-class HIV-1 attachment inhibitor.\",\"authors\":\"Philip M Grant, Michael J Kozal\",\"doi\":\"10.1097/COH.0000000000000712\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Purpose of review: Fostemsavir is a recently Food and Drug Administration-approved HIV-1 attachment inhibitor that binds to HIV-1 gp120 and prevents viral attachment to the cellular CD4 receptor. Here, we review the pharmacology, efficacy, tolerability, and resistance profile of fostemsavir.Recent findings: Fostemsavir is well tolerated and maintains virologic activity in individuals harboring multidrug-resistant HIV-1. In conjunction with optimal background therapy, a majority of heavily treatment-experienced clinical trial participants treated with fostemsavir achieved virologic suppression.Summary: The approval of fostemsavir represents an important advance for individuals harboring multidrug resistant HIV-1 due to its novel mechanism of action and lack of cross-resistance to other antiretrovirals. Further study will better define the role of resistance testing for fostemsavir and fostemsavir's potential role outside of salvage therapy in heavily treatment-experienced individuals.\",\"PeriodicalId\":10949,\"journal\":{\"name\":\"Current Opinion in HIV and AIDS\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.5000,\"publicationDate\":\"2022-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"4\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Opinion in HIV and AIDS\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/COH.0000000000000712\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in HIV and AIDS","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/COH.0000000000000712","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 4

摘要

综述目的:Fostemsavir是美国食品和药物管理局(fda)最近批准的一种HIV-1附着抑制剂，可结合HIV-1 gp120并阻止病毒附着于细胞CD4受体。在这里，我们回顾了fostemsaver的药理学，疗效，耐受性和耐药概况。最近的研究发现:Fostemsavir在携带多重耐药HIV-1的个体中具有良好的耐受性并保持病毒学活性。与最佳背景治疗相结合，大多数接受过fostemsaver治疗的临床试验参与者获得了病毒学抑制。摘要:由于其新的作用机制和对其他抗逆转录病毒药物缺乏交叉耐药，fostemsavir的批准代表了多药耐药HIV-1个体的重要进展。进一步的研究将更好地确定fostemsavir耐药试验的作用，以及fostemsavir在重度治疗经验个体的挽救治疗之外的潜在作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Fostemsavir: a first-in-class HIV-1 attachment inhibitor.

Purpose of review: Fostemsavir is a recently Food and Drug Administration-approved HIV-1 attachment inhibitor that binds to HIV-1 gp120 and prevents viral attachment to the cellular CD4 receptor. Here, we review the pharmacology, efficacy, tolerability, and resistance profile of fostemsavir.

Recent findings: Fostemsavir is well tolerated and maintains virologic activity in individuals harboring multidrug-resistant HIV-1. In conjunction with optimal background therapy, a majority of heavily treatment-experienced clinical trial participants treated with fostemsavir achieved virologic suppression.

Summary: The approval of fostemsavir represents an important advance for individuals harboring multidrug resistant HIV-1 due to its novel mechanism of action and lack of cross-resistance to other antiretrovirals. Further study will better define the role of resistance testing for fostemsavir and fostemsavir's potential role outside of salvage therapy in heavily treatment-experienced individuals.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Current Opinion in HIV and AIDS IMMUNOLOGY-INFECTIOUS DISEASES

CiteScore

7.40

自引率

7.30%

发文量

115

审稿时长

6-12 weeks

期刊介绍： Published bimonthly and offering a unique and wide ranging perspective on the key developments in the field, each issue of Current Opinion in HIV and AIDS features hand-picked review articles from our team of expert editors. With six disciplines published across the year – including HIV and ageing, a HIV vaccine, and epidemiology – every issue also contains annotated reference detailing the merits of the most important papers.